EP Patent

EP4444304A4 — METHODS OF TREATMENT FOR PRIMARY IMMUNODEFICIENCY

Assigned to X4 Pharmaceuticals Inc · Expires 2025-12-17 · 0y expired

What this patent protects

Patent listed against Xolremdi.

Drugs covered by this patent

Xolremdi (MAVORIXAFOR) · X4 Pharms

Patent Metadata

Patent number: EP4444304A4
Jurisdiction: EP
Classification: —
Expires: 2025-12-17
Drug substance claim: No
Drug product claim: No
Assignee: X4 Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.